O Caixa Empreender Award atribuiu um valor de investimento adicional, no valor de 100 mil euros, ao projeto que mais se destacou de um conjunto de 7 startups, previamente selecionadas no âmbito dos programas de aceleração que contam com o apoio do Grupo CGD, BGI, Lisbon Challenge e ACT by COTEC. A Nanoinspire foi uma das startups presentes no Caixa Empreender. #thefuturefromscratch Mais sobre o objetivo deste evento em: http://bit.ly/1CzA5BV

1. 27TH JANUARY 2015
NANOSCALE THERAPEUTIC SOLUTIONS FOR
REGENERATIVE MEDICINE

2. CARDIOVASCULAR
DISEASE
DIABETES
BED-BOUND
IMPAIRED
BLOOD
CIRCULATION
COMPROMISED
HEALING
CHRONIC WOUNDS
Do not heal for more
than 6 weeks
High probability of local and
systemic infection
High risk of Amputations
Frequent Treatments
Pain and Impaired Mobility
MAJOR PROBLEMS
PROBLEM & NEED

3. Source: MedMarket Diligence, 2013
50 million chronic wound patients worldwide
Standard care
does not cure
70% of these
wounds
THE PROBLEM WE
ARE ADDRESSING
PROBLEM & NEED

4. The first s
derived gel for topic
application
N A N O in SPIRE
The first stem cell
derived gel for topic
lication in chronic
wounds
What is
Itisproduct
wounds
Blood ofhealth
potential.
abilityto
wound,
How can SKINHEALER
Accelerated healing
Lesstimespentinhospital
N A N Oin SPIRE
m cell
derived gel for topic
in chronic
What is SKINHEALER?
producttotreatdiabetic,venousandpressurechronic
wounds.Itispurifiedfromstemcellsofthe
ofhealthydonors,whichconfers
potential.ThemajorcomponentofSKINHEALER
tostimulatevascularizationandre
wound,rapidlystimulatingthehealing.
What does
SKINHEALER
chronic skin wounds
diseaseconditions:
causedbyunrelievedpressureresultingin
damagetounderlyingtissue;
ulcers,whichdevelopasaresultofinsufficient
flowofbloodthroughveinsincertainareas;
diabetic ulcers
woundsoccurringonthefeetofdiabetics
How can SKINHEALER help me?
ccelerated healing,andthepossibilityofdoing
Lesstimespentinhospital,andlower cost
treatdiabetic,venousandpressurechronic
oftheUmbilical Cord
,whichconferstoitahighregenerative
SKINHEALER hasthe
ationandre-epithelizationofthe
.
does SKINHEALER do?
SKINHEALER accelerates the healing of
chronic skin wounds,whichresultfromdifferent
diseaseconditions:pressure ulcers,whichare
causedbyunrelievedpressureresultingin
damagetounderlyingtissue;venous stasis
,whichdevelopasaresultofinsufficient
flowofbloodthroughveinsincertainareas;
diabetic ulcers whicharetypicallychronic
ringonthefeetofdiabetics,dueto
inefficientbloodcirculation.
help me?
ossibilityofdoingself application.
lower costs duetofasterrecovery.
ing of
,whichare
causedbyunrelievedpressureresultingin
venous stasis
,whichdevelopasaresultofinsufficient
flowofbloodthroughveinsincertainareas;
whicharetypicallychronic
,dueto
REGENERATIVE
Thegelis
composedofstem
cellderived
componentswhich
deliverregenerative
factorstothe
injuredtissue.
SELF
ADMINISTERED
Itistheonlyproductin
themarketforthe
treatmentofchronic
woundsthatcanbe
selfadministered
uponmedical
counseling
CELLFREE
ADVANCEDTHERAPY
Itistheonlycell-free
AdvancedTherapy
Productinthemarket
SELF
D
roductin
themarketforthe
ofchronic
thatcanbe
administered,
uponmedical
counseling.
Umbilical Cord Blood
“I have trouble believing that stem cells will survive
the harsh environment of the wound.”
Professor Martins-Green
Board of Directors of the Wound Healing Society
Patent for the use of Stem
Cells in Chronic Wounds
TECHNOLOGY
In collaboration with

5. The first s
derived gel for topic
application
N A N O in SPIRE
The first stem cell
derived gel for topic
lication in chronic
wounds
What is
Itisproduct
wounds
Blood ofhealth
potential.
abilityto
wound,
How can SKINHEALER
Accelerated healing
Lesstimespentinhospital
N A N Oin SPIRE
m cell
derived gel for topic
in chronic
What is SKINHEALER?
producttotreatdiabetic,venousandpressurechronic
wounds.Itispurifiedfromstemcellsofthe
ofhealthydonors,whichconfers
potential.ThemajorcomponentofSKINHEALER
tostimulatevascularizationandre
wound,rapidlystimulatingthehealing.
What does
SKINHEALER
chronic skin wounds
diseaseconditions:
causedbyunrelievedpressureresultingin
damagetounderlyingtissue;
ulcers,whichdevelopasaresultofinsufficient
flowofbloodthroughveinsincertainareas;
diabetic ulcers
woundsoccurringonthefeetofdiabetics
How can SKINHEALER help me?
ccelerated healing,andthepossibilityofdoing
Lesstimespentinhospital,andlower cost
treatdiabetic,venousandpressurechronic
oftheUmbilical Cord
,whichconferstoitahighregenerative
SKINHEALER hasthe
ationandre-epithelizationofthe
.
does SKINHEALER do?
SKINHEALER accelerates the healing of
chronic skin wounds,whichresultfromdifferent
diseaseconditions:pressure ulcers,whichare
causedbyunrelievedpressureresultingin
damagetounderlyingtissue;venous stasis
,whichdevelopasaresultofinsufficient
flowofbloodthroughveinsincertainareas;
diabetic ulcers whicharetypicallychronic
ringonthefeetofdiabetics,dueto
inefficientbloodcirculation.
help me?
ossibilityofdoingself application.
lower costs duetofasterrecovery.
ing of
,whichare
causedbyunrelievedpressureresultingin
venous stasis
,whichdevelopasaresultofinsufficient
flowofbloodthroughveinsincertainareas;
whicharetypicallychronic
,dueto
REGENERATIVE
Thegelis
composedofstem
cellderived
componentswhich
deliverregenerative
factorstothe
injuredtissue.
SELF
ADMINISTERED
Itistheonlyproductin
themarketforthe
treatmentofchronic
woundsthatcanbe
selfadministered
uponmedical
counseling
CELLFREE
ADVANCEDTHERAPY
Itistheonlycell-free
AdvancedTherapy
Productinthemarket
SELF
D
roductin
themarketforthe
ofchronic
thatcanbe
administered,
uponmedical
counseling.
Umbilical Cord Blood
Patent for the use of Stem
Cells in Chronic Wounds
TECHNOLOGY
Increase the activity
Non-Cellular
Product with High
Therapeutic Activity
NIN-B101

6. Complete healing in
15 days
Accelerates
Healing
Promotes
Vascularization
Stimulates Skin
Growth
CONTROL
NIN-B101
DAY 0 DAY 10
PRODUCT AND BENEFITS
100% mice respond
to treatment

7. COMPETITORS AND
DIFFERENTIATION
20% improvement
compared to
Control
Improvement
from DAY 1
Improvement
from DAY 5

8. Product features/
customer benefits
Regranex Dermagraft Autologel SKINHEALER
Time to Heal + + ++ +++
Responsiveness
50% in
Humans
30% in
Humans
80% in
Humans
100% in
Animals
Safety + + +++ +++
Hipoalergenic + + + ++
Easy Application +++ + ++ +++
COMPETITORS AND
DIFFERENTIATION

9. OVERALL
ADVANCED THERAPIES
EUROPE AND USA
• $2.5BN
• $970M
• $800M
2013 2021CHRONIC WOUNDS
$6.5BN
$3.2BN
$2.7BN
Source: MedMarket Diligence, 2013; Smith and Nephew, Global Industry Analyst Report 2007
Market growth driven by increased incidence of obesity and diabetes combined with an aging population.
MARKET

10. TIMELINE
TODAY
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Investigational New Drug
Approval of Clinical Trial
Results from Clinical
Trial Phase 1-2
Results from Clinical
Trial Phase 3
Commercialization
PRE-CLINICAL
DEVELOPMENT
€2.5M
PHASE 3 CLINICAL TRIAL
€19M REVIEW AND
APPROVAL
PROFIT
PHASE 1-2
CLINICAL TRIAL
€5M
POSSIBLE EXIT 1
POSSIBLE EXIT 2

11. M€
FINANCIALS

12. SPECIALIZED TREATMENTS FOR ISCHEMIC DISEASES
MYOCARDIAL
INFARCTION
PERIPHERAL ARTERIAL
DISEASE
PIPELINE
IN COLLABORATION
WITH:

13. • Joana Simões
Correia, PhD
• Bsc Chemistry
• PhD Human
Biology
• Researcher
• Ricardo Neves,
PhD
• Bsc Biology
• Dphil Biology
• Researcher
• Lino Ferreira,
PhD
• Bsc Biochemistry
• PhD
Biotechnology
• Researcher
• Luísa Marques,
MBA
• Bsc Management
• MBA
• Business
Developer
Supported by
TEAM
AND

14. Changing the way we treat chronic wounds, forever.

15. THANK YOU
nanoinspire.team@gmail.com